Date: 2014-06-04
Type of information: R&D agreement
Compound: DuoBody® and HexaBody™ technology platforms
Company: Genmab (Denmark) - undisclosed large Biotechnology company
Therapeutic area: undisclosed
Type agreement: R&D
Action mechanism: The DuoBody platform is a platform for the discovery and development of bispecific antibodies. Bispecific antibodies bind to two different epitopes either on the same, or on different targets (also known as dual-targeting) which may improve the antibodies\' specificity and efficacy in inactivating the disease targets. Genmab\'s DuoBody platform generates bispecific antibodies via a fast and broadly applicable process which is easily performed at standard bench, as well as commercial, manufacturing scale. HexaBody technology allows for the creation of potent therapeutics by inducing antibody hexamer formation (clusters of six antibodies). The HexaBody platform builds on natural antibody biology and enhances complement-mediated killing (complement-dependent cytotoxicity (CDC)), allowing antibodies with limited or absent CDC to be transformed into potent cytotoxic antibodies. The HexaBody technology can be directed to any antigen or target, including those implicated in cancer and infectious diseases. It can be combined with Genmab\'s DuoBody platform as well as other antibody technologies.
Disease: undisclosed
Details: * On June 4, 2014, Genmab announced a research collaboration with an undisclosed Biotechnology company which would use and evaluate Genmab\'s proprietary antibody technologies, the DuoBody and HexaBody platforms.
Financial terms: The financial terms of the agreement have not been disclosed. This agreement will not have a material impact on Genmab\'s financial results and cash position.
Latest news:
